Zytram

Quick links to important sections

Zytram

Selected form

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zytram

Quick Facts

Property Description
Active ingredient Tramadol Hydrochloride
Form Oral tablets (Immediate- or Extended-release)
Pharmacological class Opioid analgesic / Central-acting analgesic
Common use Management of moderate to moderately severe pain
Origin Synthetic

What Type of Medicine is Zytram?

Zytram is a prescription-only pharmaceutical product classified as an opioid analgesic and a central-acting analgesic. Its active ingredient is Tramadol Hydrochloride, a synthetic compound developed for systemic pain management. This pharmacological class is clinically recognized for providing effective systemic relief in patients requiring management of moderate to moderately severe pain when relief cannot be adequately achieved through agents with less potent mechanisms. Tramadol acts in the brain to change how your body feels and responds to pain.

Composition and Form of Zytram

The single active component in this medication is Tramadol Hydrochloride, formulated as a single-component product for oral administration. The primary presentation is as oral tablets. Zytram is commercially available in both immediate-release formats, which allow for rapid onset, and extended-release formats, which are specifically designed to deliver the Tramadol Hydrochloride consistently over many hours. The availability of both formats allows clinicians to match the formulation to the temporal needs of the patient's pain profile.

The Dual Principle Behind Tramadol's Analgesic Effect

The core efficacy of this medicine relies on its unique dual principle. It acts by engaging the body's mu-opioid receptors, which are vital components of the pain signal pathway. Simultaneously, the compound modulates the reuptake of specific neurotransmitters, including serotonin and norepinephrine, which are natural chemicals that influence the body's inherent response to pain. Tramadol and its active metabolite act as a weak opioid agonist and inhibitor of norepinephrine and serotonin reuptake. This combined engagement of both the opioid receptor pathway and the neurotransmitter systems is the fundamental mechanism allowing it to mitigate the perception of pain systemically.

Regulatory References

  1. MedlinePlus

What side effects are possible with Zytram?

Possible Side Effects and Safety Information: Zytram

This information describes the documented adverse reactions and safety risks associated with Zytram (tramadol hydrochloride prolonged-release tablets), as officially recognized by government regulatory agencies.

Serious Warnings and Risks

Regulatory agencies emphasize the potential for Addiction, Abuse, and Misuse, which can lead to overdose and death. The most serious risk is Life-Threatening Respiratory Depression (slowed or stopped breathing), particularly during the start of treatment or when used with other sedating medications or alcohol. There is a risk of Neonatal Opioid Withdrawal Syndrome in newborns if the medication is used long-term during pregnancy.

Other serious risks include Serotonin Syndrome, Seizures/Convulsions (which can occur even at recommended doses), and Severe Hypotension (low blood pressure).

Common Adverse Reactions

The following side effects are documented as Very Common (affecting more than 1 in 10 patients) or Common (affecting 1 to 10 in 100 patients) in clinical trials:

Frequency Adverse Reaction
Very Common Nausea, Dizziness
Common Constipation, Vomiting, Somnolence (Drowsiness), Headache, Dry mouth, Pruritus (Itching), Sweating

Population and Usage Restrictions

  • Contraindications: Zytram is not recommended for use in children under 12 years of age or for post-operative management in adolescents following tonsillectomy/adenoidectomy. It is also contraindicated in patients with severe respiratory depression, severe hepatic or renal impairment, or those taking Monoamine Oxidase Inhibitors (MAOIs).
  • Tablet Integrity: Tablets must be swallowed whole. Cutting, crushing, or chewing the tablet releases a potentially fatal dose immediately.
  • Dependence and Withdrawal: Prolonged use can lead to physical dependence and tolerance. Abrupt discontinuation may cause withdrawal symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Zytram (Tramadol Hydrochloride) overdose may present with documented, severe clinical manifestations affecting the central nervous system and cardiorespiratory function. Officially documented signs of overdose include profound sedation, somnolence, and coma, alongside the potential for generalized seizures (convulsions). The most severe, life-threatening outcomes involve the respiratory system, specifically life-threatening respiratory depression and potential respiratory arrest, which can escalate rapidly to severe hypotension and cardiovascular collapse.

The regulatory requirements strictly mandate that individuals seek immediate medical attention and contact emergency services immediately for any suspected overdose. Official guidance specifies that emergency management is primarily symptomatic and supportive, including measures to secure the airway and support vital functions. The opioid antagonist Naloxone is an intervention noted in regulatory documents, but its action may be only partial in reversing all effects. Consequently, close hospital monitoring is required to manage potential recurrences of CNS or respiratory depression.

A critical regulatory warning emphasizes that accidental ingestion of even one dose, particularly of the extended-release formulation and especially by children, carries a documented risk of fatal overdose. This population-specific note highlights the severe danger of accidental exposure.

Therapeutic Uses of Zytram

What Zytram Treats: Main Uses and Benefits

Zytram may be part of symptomatic management for pain that is classified as moderate to moderately severe. This medication is applied when symptoms are severe enough to require an opioid analgesic and when alternative treatment options are inadequate.


This analgesic is relevant for easing symptoms related to physical discomfort, commonly used to help manage pain associated with conditions characterized by periods of heightened symptoms, such as chronic ongoing discomfort, post-operative pain, and pain associated with conditions like osteoarthritis. It may provide support that contributes to easing the overall symptom load and assists with maintaining functional stability.

For pain that is persistent or refractory to other treatments, Zytram may contribute to symptomatic relief that helps patients cope more steadily with symptom fluctuations. This approach is relevant when supportive symptom management is appropriate for pain that is persistent.

Quick Fact: Relief for Persistent Pain

Property Description
Symptom Severity Moderate to moderately severe
Core Focus Pain requiring specialized analgesic support
Core Benefit Contributes to easing the overall symptom load
Usage Context Acute episodes or sustained chronic pain

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zytram — Official Regulatory Information

Zytram (Tramadol Hydrochloride) is an opioid analgesic, and its use is strictly governed by regulatory eligibility rules based on patient population, clinical status, and organ function.

Eligibility Status
Use is Contraindicated (Must Not Be Used)
  • Children younger than 12 years of age.
  • Children younger than 18 years of age following tonsillectomy and/or adenoidectomy.
  • Patients with significant respiratory depression or acute, severe bronchial asthma.
  • Patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Patients with a known hypersensitivity to tramadol, other opioids, or any component of the formulation.
  • Patients currently using or having used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
Restricted or Conditional Use
  • Severe Organ Impairment: Use of the extended-release formulation is not recommended in patients with severe hepatic (liver) or renal (kidney) impairment, as defined by official labeling.
  • Pediatric Avoidance: Use should be avoided in adolescents 12 to 18 years of age who have specific risk factors for breathing problems, such as severe lung disease or obesity.
  • Pregnancy and Lactation: Use during pregnancy is generally restricted due to the risk of neonatal opioid withdrawal syndrome. Use while breastfeeding is not recommended by regulatory authorities.
  • Seizure Risk: Patients with a history of epilepsy or an increased risk for seizures should only be treated under compelling circumstances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zytram (Tramadol Hydrochloride) is subject to several interaction patterns formally documented in regulatory sources, leading to required restrictions and prohibitions.


Pharmacodynamic and Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited and must not occur within 14 days of MAOI therapy. Zytram is also officially contraindicated during acute intoxication with substances such as alcohol, opioids, or other psychotropic drugs. Combining Zytram with CNS Depressants (including alcohol and benzodiazepines) carries a documented, enhanced risk of profound sedation and respiratory depression. Co-administration with Serotonergic Drugs (e.g., SSRIs, Triptans, St. John’s Wort) is associated with an increased risk of Serotonin Syndrome and Seizures.


Metabolic and Exposure Effects

Interactions involving the hepatic CYP2D6 and CYP3A4 enzymes officially modify Zytram's exposure. CYP2D6 Inhibitors (e.g., fluoxetine, quinidine) may result in increased tramadol plasma concentrations and decreased levels of the active M1 metabolite. Conversely, CYP3A4 Inducers (e.g., carbamazepine) may reduce the drug's overall analgesic effect. Altered prothrombin time/INR has also been reported with warfarin co-administration.


Regulatory Context and Population Notes

Official labeling restricts use in children younger than 12 years of age and for certain post-operative procedures in those under 18. Elderly patients are noted to have an increased risk for hyponatremia with concomitant medications. Genetic factors like the CYP2D6 ultra-rapid metabolizer status are officially recognized as increasing the risk of opioid toxicity.

Mechanism of Action

Dual Action on Central Pain Signaling

Zytram works through two distinct, complementary mechanisms in the central nervous system (CNS). The first involves activating the mu-opioid receptor (muOR) through its active metabolite, O-desmethyl-tramadol (M1), which directly suppresses the ascending transmission of nociceptive signals in the spinal cord and brain. The second mechanism is the inhibition of norepinephrine and serotonin reuptake, which strengthens the body's natural descending pain-inhibitory pathways.


Modulating Neurotransmitter Dynamics

This mechanism focuses on altering the concentration of key signaling molecules—norepinephrine (NE) and serotonin (5-HT)—within nerve synapses by blocking the transporters that remove them. This sustained presence of monoamines contributes to regulating nociceptive input by influencing activity within neural pathways that process nociception.


Metabolite-Driven Efficacy

The full extent of Zytram's muOR agonism depends on the body's ability to convert the parent drug into the M1 metabolite via liver enzymes. M1 is the primary driver of the drug's muOR agonism, initiating the molecular cascade that results in suppression of ascending nociceptive transmission and other downstream muOR effects like decreased gastrointestinal motility. Variability in the enzyme that produces M1 can therefore directly influence the magnitude of muOR activation.

Dosage and Administration Information

How to Use Zytram

Zytram (Tramadol Hydrochloride) is administered primarily via the oral route as tablets or capsules, although a solution for intravenous, intramuscular, or subcutaneous injection is also available for clinical use. The general pattern of use is defined by the specific formulation used.


Dosage and Administration Patterns

Pattern Immediate-Release (IR) Oral Tablets Extended-Release (ER) Oral Tablets/Capsules
Dosing Frequency Administered as needed, typically every 4 to 6 hours. Administered once daily (Q.D.).
Maximum Daily Dose Typically restricted to 400 mg per day. Typically restricted to 300 mg per day.
Intake Condition May be taken without regard to food. Must be swallowed whole and should not be crushed, split, chewed, or dissolved.

Population-Specific Use and Duration

The treatment duration should be maintained for the shortest period necessary and requires periodic re-evaluation to confirm the continued need for the medicine. Specific dosing adjustments are mandated for certain populations. For instance, the total daily dose of IR formulations is typically restricted to 300 mg in patients over 75 years of age. Furthermore, dose frequency or total amount must be reduced in individuals with significant renal or hepatic impairment due to altered clearance of the compound, with ER formulations often being discouraged in these populations. If a dose is missed, standard instructions advise taking it promptly unless it is close to the time for the next scheduled dose, in which case the patient should skip the missed dose and resume the normal schedule, without doubling the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zytram

The research for Zytram (Tramadol Hydrochloride) focuses on evaluating how it was observed in clinical studies exploring how symptoms change over time for different types of pain. The evidence primarily comes from randomized controlled trials (RCTs) and systematic reviews, which researchers studied for outcomes related to physical discomfort.


Evidence for Use in Chronic Non-Cancer Pain (CNCP)

Research has primarily examined the use of Zytram in adults with conditions characterized by fluctuating or episodic manifestations, such as pain related to osteoarthritis. The studies conducted during periods of increased symptom activity were usually short-term, randomized trials, often comparing the medication to a placebo. These trials monitored patient-reported outcomes describing perceived discomfort.

Studies recorded measurements of changes in pain intensity compared to placebo in these short-term settings. The research also explored outcomes reflecting daily functioning, but findings related to these outcomes were heterogeneous across different studies. The follow-up durations were limited in most pivotal randomized trials, meaning that long-term effects are not fully established regarding sustained functional improvement.


Evidence for Use in Acute Pain Management

For short-term, acute episodes, such as those associated with surgery, studies focused on episodes where symptoms become more noticeable. Researchers evaluated outcomes describing episodic or acute changes, such as the time it took for patients to report initial relief and the consumption of supplementary pain medication. Data show patterns related to temporary changes in pain intensity over the immediate post-operative phase. In some studies, measured outcomes were observed in patterns consistent with other agents studied in acute pain models. However, these results apply only to the specific surgical populations and controlled conditions studied.


What Scientific Research Considers Uncertain or Gaps

Scientific reviews frequently note that sample sizes were modest in some studies, and evidence quality varies across studies, contributing to the fact that certainty remains low for certain measured outcomes. Comparative evidence is lacking for many direct head-to-head trials against all available alternative pain management strategies. Research is ongoing to further examine long-term follow-up data and address the limitations noted in the existing evidence base.

Frequently Asked Questions (FAQ)

Common questions about Zytram (FAQ)


Q: Does Zytram interact with common over-the-counter pain relievers?

A: Official labeling identifies interaction risks with agents like warfarin, a blood thinner. The co-use of Zytram with any medication, including OTC products, should be discussed with a healthcare provider due to documented interaction patterns.


Q: Are there any specific foods or drinks to avoid while using Zytram?

A: Regulatory documents explicitly state that Zytram should not be used during acute intoxication with substances like alcohol. Combining the two is associated with increased risks. Furthermore, extended-release forms must generally be swallowed whole and not crushed, chewed, or split, regardless of whether they are taken with food or on an empty stomach.


Q: Can Zytram affect my ability to drive or operate machinery?

A: Official labeling contains a specific warning that Zytram may impair your ability to perform potentially hazardous tasks, such as driving a car or operating heavy machinery. This warning is based on the common side effects of the medication, which include dizziness and somnolence (drowsiness).


Q: What should I do if I experience a very common side effect?

A: Regulatory-sourced patient information advises that if common side effects, such as nausea or dizziness, persist or become severe, official information suggests discussing persistent or severe common side effects with a healthcare provider. Patients are also provided with warnings about specific, rare, or serious side effects that require immediate medical attention.


Q: What happens if I miss a time to use Zytram?

A: For most formulations, the instruction is to take the missed dose as soon as it is remembered. However, if it is already close to the time for your next scheduled dose, the regulatory instruction is to skip the missed dose and resume your normal schedule. The instruction is to not double the dose to compensate for a missed amount.


Q: Is Zytram safe to use during pregnancy? (purely descriptive answer needed)

A: Regulatory bodies generally advise against the use of Zytram for long periods during pregnancy. This restriction is due to the documented risk of Neonatal Opioid Withdrawal Syndrome in the newborn. Official guidance recommends avoiding use unless the potential benefit outweighs the potential risk to the fetus.


Q: Does Zytram interact with alcohol?

A: Yes, Zytram interacts with alcohol. Official documents state that use is contraindicated during acute intoxication with alcohol. Combining Zytram with alcohol can significantly enhance the risk of serious side effects, including profound sedation and potentially life-threatening respiratory depression (slowed breathing).


Q: Is Zytram safe to use if I have kidney problems? (descriptive only)

A: Official information states that use of Zytram is restricted for patients with severe renal (kidney) impairment. The extended-release formulation is officially not recommended in this population, and the amount or frequency of the immediate-release formulation must be adjusted by a healthcare provider, requiring adjustment to the amount or frequency by a healthcare provider.


Q: Can Zytram be used by people with a history of heart issues? (descriptive only)

A: Official safety warnings include the documented risk of Severe Hypotension (low blood pressure) when starting Zytram therapy. This documented risk emphasizes the importance of discussing pre-existing heart or circulatory conditions with a healthcare provider prior to use.


Q: Can Zytram cause long-term side effects?

A: Regulatory safety warnings address risks associated with prolonged use, including the potential for physical dependence and the development of tolerance. Official guidance advises that long-term treatment requires careful and regular re-evaluation.


Q: How long does it usually take to feel the effects of Zytram?

A: Official clinical pharmacology documents state that for immediate-release formulations, the time to reach the maximum concentration of the active ingredient is generally around two to three hours after taking it by mouth. The extended-release form is designed to take longer, providing a steady release over the day.


Q: Is Zytram known to be sedating?

A: Yes, official regulatory documents list Somnolence (drowsiness) as a common adverse reaction experienced by patients in clinical trials. Dizziness is also listed as a very common adverse reaction. Due to these effects, users are warned about driving or operating machinery.


Q: How quickly does Zytram leave the body?

A: Official pharmacological data indicates that the average terminal elimination half-life of the parent compound for a single immediate-release dose is approximately 6.3 hours. The body typically takes about five half-lives for a substance to be substantially eliminated.


Q: What if I'm already using supplements? Can I still use Zytram?

A: Official regulatory warnings explicitly list an interaction risk with the herbal supplement St. John's Wort. This is due to an increased risk of serious conditions like Serotonin Syndrome and seizures. Warnings generally advise caution with any agents that affect the central nervous system.


Q: Is it possible to become dependent on Zytram? (focus on regulatory warnings)

A: Yes. Regulatory documents state that prolonged use of Zytram carries a risk of developing physical dependence and tolerance. The drug also has warnings regarding the risk of Addiction, Abuse, and Misuse.


Q: How long can Zytram be used safely?

A: Official guidance states that treatment duration should be maintained for the shortest period necessary. For long-term use, official guidance states that treatment should be maintained for the shortest period necessary and requires careful, regular re-evaluation.


Q: Does Zytram lose its effectiveness over time? (tolerance/desensitization)

A: Yes, official regulatory documents explicitly state that prolonged use can result in the development of tolerance. Tolerance is defined as the need for progressively higher doses to achieve the original effect, and is a concept acknowledged in the official labeling.


Q: Are there any specific tests needed before starting Zytram?

A: Official information acknowledges that an individual's genetic status regarding the CYP2D6 enzyme can influence effectiveness and safety risk. Further discussion on monitoring or specific testing should occur with a healthcare provider.


Q: Does Zytram affect my mood or sleep?

A: Official documentation notes common adverse effects like Somnolence (drowsiness) and Dizziness, which can potentially affect sleep patterns and state of mind. The risk of Serotonin Syndrome is noted, which can include changes in mental status.


Q: Are there any known interactions between Zytram and herbal remedies?

A: Yes. Regulatory documents specifically warn against combining Zytram with the herbal supplement St. John's Wort. This combination is associated with an increased risk of severe adverse events, including Serotonin Syndrome and the potential for seizures.


Q: What is the risk of having a serious interaction with Zytram?

A: The risks of serious interactions are clearly documented in official sources, particularly with co-use of CNS Depressants (including alcohol) and Serotonergic Drugs. These combinations carry heightened regulatory warnings for respiratory depression (slowed breathing) and Serotonin Syndrome, respectively.


Q: Does the time of day I use Zytram matter?

A: Yes, the recommended timing depends on the formulation. The extended-release (ER) forms are generally prescribed to be taken once daily. The immediate-release (IR) forms are prescribed to be taken as needed, usually every 4 to 6 hours, requiring adherence to a regular schedule as determined by the prescribing healthcare provider.


Q: Do official documents mention any potential for withdrawal effects with Zytram?

A: Yes. Official warnings indicate that physical dependence may develop with prolonged use. Abrupt discontinuation of Zytram may result in recognized withdrawal symptoms. Gradual dose reduction (tapering) is typically advised by regulatory guidelines when stopping the medicine.


Q: Are there different forms or strengths of Zytram available?

A: Official prescribing information lists Zytram as available in both immediate-release and extended-release oral forms. These formulations are typically offered in multiple strengths to accommodate different patient dosing needs, which are determined by the prescribing healthcare provider.

How should Zytram be stored and disposed of?

How to Store and Dispose of Zytram?

Zytram (Tramadol Hydrochloride) is a controlled substance with specific storage and disposal requirements to ensure product integrity and prevent misuse or accidental overdose.

Storage Conditions

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from light and moisture. It must remain in its original, tightly closed container and must not be frozen.

Child-Safety and Disposal

This medication must be kept securely and out of the sight and reach of children due to the risk of fatal overdose. Disposal of unused or expired Zytram should primarily utilize an authorized drug take-back program. Regulatory documents advise against throwing the medicine away in household trash or pouring it down wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zytram found in:

A-Z Index: